Osaic Holdings’s KalVista Pharmaceuticals KALV Stock Holding History

Osaic Holdings’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$40.4K	Sell	2,006 -19,931	-91%	-$321K	﹤0.01%	5374
2025 Q4	$354K	Sell	21,937 -1,424	-6%	-$18.9K	﹤0.01%	3645
2025 Q3	$285K	Buy	23,361 +1,446	+7%	+$20K	﹤0.01%	3916
2025 Q2	$248K	Buy	+21,915	New	+$268K	﹤0.01%	3760
2025 Q1	–	Sell	-20,804	Closed	-$176K	–	7588
2024 Q4	$176K	Buy	20,804 +144	+0.7%	+$1.49K	﹤0.01%	3713
2024 Q3	$239K	Sell	20,660 -720	-3%	-$9.06K	﹤0.01%	3506
2024 Q2	$252K	Buy	+21,380	New	+$250K	﹤0.01%	3351
2022 Q3	–	Sell	-100	Closed	-$1K	–	7389
2022 Q2	$1K	Hold	100	–	–	﹤0.01%	7096
2022 Q1	$1K	Hold	100	–	–	﹤0.01%	7063
2021 Q4	$1K	Hold	100	–	–	﹤0.01%	7200
2021 Q3	$2K	Hold	100	–	–	﹤0.01%	6864
2021 Q2	$2K	Hold	100	–	–	﹤0.01%	6715
2021 Q1	$3K	Buy	+100	New	+$2.63K	﹤0.01%	6371

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Osaic Holdings's KALV Position: Q1 2026 in Review

Osaic Holdings reduced its KalVista Pharmaceuticals (KALV) stake by 91% in Q1 2026, selling an estimated $321K and leaving 2,006 shares worth $40.4K. The position accounts for ﹤0.01% of the portfolio, ranked #5374.

Osaic Holdings first reported a position in KALV in Q1 2021 and has held it in 13 quarters since. The position peaked at $354K in Q4 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Osaic Holdings held 2,006 shares of KalVista Pharmaceuticals worth $40.4K as of Q1 2026.
Osaic Holdings sold 19,931 KalVista Pharmaceuticals shares in Q1 2026, an estimated $321K.
KalVista Pharmaceuticals made up ﹤0.01% of Osaic Holdings's portfolio in Q1 2026, its #5374 holding.
Osaic Holdings first reported a position in KalVista Pharmaceuticals in Q1 2021 and has held it in 13 quarters since.
Osaic Holdings's KalVista Pharmaceuticals position peaked at $354K in Q4 2025.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.